<DOC>
	<DOCNO>NCT00593853</DOCNO>
	<brief_summary>The purpose study determine methylphenidate improve fatigue men undergo hormonal therapy prostate cancer LHRH-agonist .</brief_summary>
	<brief_title>Efficacy Study Methylphenidate Hydrochloride Reduce Fatigue Prostate Cancer Patients Receiving Hormone Therapy</brief_title>
	<detailed_description>This study determine methylphenidate improves fatigue men undergo hormonal therapy prostate cancer . Fatigue common problem experience cancer patient . Those patient receive chemotherapy radiation especially vulnerable fatigue , men prostate cancer receive hormonal therapy LHRH-agonist ( androgen deprivation therapy ) . Eligible men randomize daily dose 10 mg methylphenidate placebo total treatment period 12 week . Subjects monitor change fatigue mood period . While exact cause fatigue set unknown , study hopefully lead well understanding process provide patient much-needed remedy fatigue</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion : Age &gt; 18 ≤ 85 year Histologically confirm prostate cancer Currently receive LHRHagonist therapy great 6 month measurable fatigue , define score &gt; 1 Bruera global fatigue severity scale OR Deemed eligible commence LHRHagonist therapy , confirmation fatigue Screening Visit 2 Have serum PSA stable decreasing base PSA trend last 2 value take least 2 month apart , recent value take least 2 month initiation LHRHagonist therapy . Have adequate liver renal function ( Bilirubin ≤ 1.5 x ULN AST , ALT Serum Creatinine &lt; 2 x ULN ) Able swallow retain oral medication Life expectancy least 1 year Able read write English ( therefore accurately complete require study questionnaire ) , understand instruction relate study procedure give write informed consent . Exclusion : Current malignancy receive treatment previous malignancy within last 3 year prostate cancer ( exception superficial bladder cancer nonmelanoma skin cancer ) Previous chemotherapy within last 5 year Anemia ( Hemoglobin &lt; 100 g/L ) Myocardial infarction within past 6 month Any unstable serious coexist medical condition ( ) include limit ; unstable poorly control coronary artery disease , chronic atrial fibrillation , uncontrolled hypertension , uncontrolled diabetes , Severe bleed disease immune disorder Severe depression define CESD score &gt; 27 History motor tic , seizure family history Tourette 's syndrome Infection HIV ( Human Immunodeficiency Virus ) , HBV ( Hepatitis B ) HCV ( Hepatitis C ) Evidence drug alcohol abuse Known hypersensitivity methylphenidate Possess contraindication methylphenidate use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>LHRH-agonist related fatigue</keyword>
</DOC>